BBIO
$67.25+0.51%
as of close, Oct 2, 2026
☾ AH $67.25 +0.51%
BridgeBio Pharma Inc.Stock · Health CareNasdaq Composite 0.03%US Stock Market 0.02%Russell 1000 0.02%Russell 3000 0.02%
BBIO — BridgeBio Pharma Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEE
10.020.030.040.050.060.070.080.0050.0M$67.25—20192021202320242026
2026-10-02
Price$67.25
MA20$75.98
MA50$73.76
Vol9.0M
Key stats
Price data
- Price
- $67.25
- Change YTD
- -12.08%
- Next earnings
- Nov 4, 2026
- Market cap
- 13.1B
- Enterprise value
- 15.1B
- Shares outstanding
- 195.5M
- 52W low
- $51.85
- 52W high
- $93.42
- From 52W high
- -28.01%
- From 52W low
- +29.70%
- 52W range
- 37%
- Beta
- 0.98
Volume
- Rel volume
- 1.05×
- 30D volume
- 2.5M
- 30D $ vol
- 177.4M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$691K
- Insider net 3M
- −$19.2M
- Insider net 1Y
- −$76.4M
Form 4 transactions by trade date, as filed; latest on file 2026-09-17.
Fundamentals
- Sales (ttm)
- 713.1M
- Sales/share
- $3.65
- EPS (ttm)
- -$3.62
- FCF (ttm)
- -435.4M
- FCF/share
- -$2.23
- Book value/share
- -$12.87
- Net margin
- -98.45%
- ROA
- -57.67%
- Current ratio
- 1.23
Growth (CAGR, ttm) · 10Y
- Sales
- +202.62%+400.68%+62.61%n/a
- Shares
- +2.26%+6.36%+5.47%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +195.93%+370.75%+54.17%n/a
- Price
- +26.24%+38.31%+7.09%n/a
- Total return
- +26.24%+38.31%+7.09%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -18.6×
- Fwd P/E
- 2424.8×
- P/S (ttm)
- 18.4×
- P/B (mrq)
- -5.2×
- EV/Sales (ttm)
- 21.2×
- FCF yield (ttm)
- -3.31%
- Buyback yield (realized, 1y)
- -2.26%
- Shareholder yield (realized, 1y)
- -2.26%
- Buyback yield (cash, ttm)
- 1.60%
- Shareholder yield (cash, ttm)
- 1.60%
Vs own 10Y history
- P/S
- 12th
Bar = where today’s multiple sits in BBIO’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-02
1D
+0.51%
5D
+2.56%
1M
-12.09%
3M
-12.88%
YTD
-12.08%
1Y
+26.22%
5Y
+40.87%
Recent filings
- Sep 17Insider sale · Kumar Neil (Chief Executive Officer · Director) sold 10,000 shares for $691K at $69.01–$69.57 under a 10b5-1 plan
- Aug 318-K · Other events
- Aug 19Insider sale · Kumar Neil (Chief Executive Officer · Director) sold 10,000 shares for $840K at $83.86–$85.65 under a 10b5-1 plan
- Aug 18Insider sale · Kumar Neil (Chief Executive Officer · Director) sold 34,980 shares for $2.9M at $81.15–$83.77 under a 10b5-1 plan
- Aug 178-K · Material definitive agreement; Other events
Financial statements
Open full BBIO financials →Loading financial statements…
Related Health Care
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| NVS | Novartis AG | -13.21% | -0.04% |
| NVO | Novo Nordisk A/S | -20.21% | -0.21% |
| SNY | Sanofi ADS | -10.23% | -1.84% |
| GSK | GSK plc American Depositary Shares (Each representing two Ordinary Shares) | -6.76% | -0.32% |
| NTRA | Natera Inc. | +26.20% | +0.46% |
| ARGX | argenx SE American Depositary Shares | -12.90% | -1.79% |
| TAK | Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | -3.09% | +0.00% |
| TEVA | Teva Pharmaceutical Industries Limited American Depositary Shares | +5.44% | +0.56% |
